Core-Shell Nanocarrier for Oxaliplatin Research
Official patent title
Hydroxyapatite-enclosed zinc phosphate nanocomposite
Arabic title: مركب نانوي من فوسفات الزنك محاط بهيدروكسي أباتيت
Invention
Invention
Problem
Oxaliplatin has clinically significant toxicity and formulation challenges, motivating carrier systems that can load the drug and control its release for preclinical investigation.
Why it matters
A well-characterized carrier could support research on drug loading and release, but improved therapeutic benefit or safety requires biological and clinical evidence.
Approach
The system uses a porous zinc-phosphate core enclosed by a hydroxyapatite shell and partly wrapped with hydrogen-bonded chitosan, then loads oxaliplatin into pores and onto the composite surfaces.
Who may benefit
Potential beneficiaries include drug-delivery researchers, oncology formulation teams, nanomedicine laboratories, pharmaceutical materials developers, and technology-transfer partners evaluating controlled-release carriers.
Potential value
The platform combines a mineral core–shell structure, a chitosan outer component, quantified porosity and drug loading, and an extended in-vitro oxaliplatin release profile in one carrier design.
Background
Background
Oxaliplatin is used in cancer chemotherapy but can cause gastrointestinal, neurological, cardiac, oral, and bone-marrow-related adverse effects, and the patent describes solubility limitations. Drug-delivery research therefore investigates carriers that can load the compound and alter its release. Hydroxyapatite offers ion-exchange capacity and surface area but is hydrophilic, while chitosan can add polymer functionality. The disclosed nanocomposite combines these materials with porous zinc phosphate. The assigned evidence reports physical structure, loading, and release conditions, not improved tumor targeting, animal outcomes, or human safety.
Technology overview
Technology overview
The carrier has a spherical porous zinc-phosphate core, a hydroxyapatite nanorod shell, and chitosan wrapped around the shell through hydrogen bonding. Claimed crystallite sizes are 7–9 nm for zinc phosphate and 6–8 nm for hydroxyapatite; BET area is 120–140 m2/g and average pore diameter is 25–35 nm. Under pH 6–8 at 20–30 °C for at least six hours, the system loads 300–350 mg oxaliplatin per gram of nanocomposite. Claimed release reaches at least 50% after 22 hours and 100% after 140 hours at pH 7.4.
Potential applications
Potential applications
- Potential use in preclinical oxaliplatin formulation and controlled-release studies.
- Potential use as a research platform for mineral–polymer drug carriers.
- Potential use in laboratory comparisons of porous anticancer-drug delivery systems.
- Potential adaptation to investigate loading of other compatible compounds.
Evidence-supported advantages
Evidence-supported advantages
- Combines a porous core, nanorod shell, and chitosan outer component.
- Defines crystallite size, surface area, pore diameter, and elemental composition.
- Reports oxaliplatin loading of 300–350 mg per gram under specified conditions.
- Provides an extended pH 7.4 release profile through 140 hours.
Development stage
Development stage
Patent publication with reported material characterization, drug loading, and in-vitro release measurements; animal efficacy, clinical safety, regulatory approval, and commercialization were not established.
Commercial opportunity
Commercial opportunity
The carrier may support sponsored preclinical work or licensing to nanomedicine and oncology-formulation developers. Advancement requires reproducible synthesis, sterile manufacturing, full physicochemical characterization, free-drug comparison, release in biologically relevant media, cellular uptake, biodistribution, efficacy, acute and chronic toxicology, immunogenicity, animal studies, clinical trials, and regulatory review.
Patent classifications
Patent classifications
WIPO IPC
- A61K9/20Preparations for medical, dental or toiletry purposes
- A61K31/555Preparations for medical, dental or toiletry purposes
- B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
CPC
- A61K9/2072Preparations for medical, dental or toiletry purposes
- A61K9/2009Preparations for medical, dental or toiletry purposes
- A61K9/5115Preparations for medical, dental or toiletry purposes
- A61K9/205Preparations for medical, dental or toiletry purposes
- A61K9/0092Preparations for medical, dental or toiletry purposes
- A61K9/5161Preparations for medical, dental or toiletry purposes
- A61K31/555Preparations for medical, dental or toiletry purposes
- A61K9/5036Preparations for medical, dental or toiletry purposes
- B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
Inventors
Inventors
- First inventorAhmed A Allam
- InventorHassan A. Rudayni
- InventorMostafa R. Abukhadra
- InventorIslam R. Sayed
Keywords
Keywords
- hydroxyapatite
- zinc phosphate
- chitosan
- nanocomposite
- oxaliplatin
- drug delivery
- controlled release
- porous carrier
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.